This inventor holds 5 USPTO granted patents and 3 EPO patents. Top assignee: Biogen Ma Inc.. Active years: 2021-2026.
Company Filing History:
Years Active: 2021-2026
Title: Jürgen Schulz: Innovator in Biopharmaceuticals
Introduction
Jürgen Schulz is a prominent inventor based in Boston, MA (US). He has made significant contributions to the field of biopharmaceuticals, particularly in the development of compounds that target Bruton's tyrosine kinase. With a total of 5 patents to his name, Schulz is recognized for his innovative approaches to drug development.
Latest Patents
Schulz's latest patents include "Condensed bi-heterocycles as inhibiting agents for Bruton's tyrosine kinase." This patent provides compounds of Formula (I) or pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, R, A, B, B, Q, and Q are as defined in the document. Additionally, he has developed another patent titled "Inhibiting agents for Bruton's tyrosine kinase," which also includes compounds of Formula (I) and methods for their use and production.
Career Highlights
Jürgen Schulz works at Biogen MA Inc., a leading biotechnology company known for its focus on neurological diseases. His work at Biogen has allowed him to explore innovative solutions in the pharmaceutical industry, contributing to advancements in treatment options for patients.
Collaborations
Some of his notable coworkers include Brian T. Hopkins and Bin Ma. Their collaboration has fostered a productive environment for research and development, leading to significant breakthroughs in their field.
Conclusion
Jürgen Schulz is a key figure in the biopharmaceutical industry, with a focus on developing innovative therapies targeting Bruton's tyrosine kinase. His contributions through patents and collaboration with esteemed colleagues highlight his commitment to advancing medical science.